GULSINE published an A2P2 September 2026 briefing.

GULSINE is an AI-driven platform that helps healthcare companies confidently define product lifespan and accelerated ageing strategies enabling faster regulatory approval and safer product release. Serving medical devices, biotech, biopharma, and combination products, our technology replaces guesswork with scientifically justified ageing protocols and lifetime predictions. Manufacturers can reduce approval timelines by up to two years, extend validated shelf life, and respond to regulatory questions with clarity and confidence. The A2P2 platform supports products containing plastic and multi-material components, helping R&D, quality, and regulatory teams streamline validation while reducing experimental burden and cost. Sustainability is built into our approach. By enabling accurate lifetime definition and reuse of high-value devices, GULSINE helps extend product life, reduce waste, and significantly lower carbon footprint across global healthcare supply chains. Since 2023, Gulsine Ltd supported medical and biopharma innovators worldwide delivering regulator-ready science, accelerated development timelines, and lab-based stability services for critical products including pacemakers, vascular grafts, biopharmaceutical bags, and medical packaging.

Founded 2023